1. Home
  2. EXPO vs LQDA Comparison

EXPO vs LQDA Comparison

Compare EXPO & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exponent Inc.

EXPO

Exponent Inc.

HOLD

Current Price

$66.56

Market Cap

3.4B

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$37.68

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXPO
LQDA
Founded
1967
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.1B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
EXPO
LQDA
Price
$66.56
$37.68
Analyst Decision
Buy
Strong Buy
Analyst Count
3
11
Target Price
$88.00
$41.00
AVG Volume (30 Days)
425.4K
1.1M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
1.86%
N/A
EPS Growth
N/A
51.81
EPS
2.07
N/A
Revenue
$582,014,000.00
$158,320,000.00
Revenue This Year
$12.75
$265.61
Revenue Next Year
$8.50
$62.82
P/E Ratio
$32.11
N/A
Revenue Growth
4.21
1031.18
52 Week Low
$63.25
$11.26
52 Week High
$83.92
$46.67

Technical Indicators

Market Signals
Indicator
EXPO
LQDA
Relative Strength Index (RSI) 45.42 55.50
Support Level $64.55 $31.75
Resistance Level $73.91 $39.19
Average True Range (ATR) 2.17 1.81
MACD 0.11 0.21
Stochastic Oscillator 54.67 79.95

Price Performance

Historical Comparison
EXPO
LQDA

About EXPO Exponent Inc.

Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: